The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
Rigel Pharmaceuticals (NASDAQ: RIGL) closed the day trading at $40.78 down -3.02% from the previous closing price of $42.05. In other words, the price has decreased by -$3.02 from its previous closing price. On the day, 0.53 million shares were traded. RIGL stock price reached its highest trading level at $42.255 during the session, while it also had its lowest trading level at $40.52.
Ratios:
For a better understanding of RIGL, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.40 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.86. For the most recent quarter (mrq), Quick Ratio is recorded 2.14 and its Current Ratio is at 2.28. In the meantime, Its Debt-to-Equity ratio is 0.52 whereas as Long-Term Debt/Eq ratio is at 0.26.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 04 ’25 when Schorno Dean L sold 2,036 shares for $20.92 per share. The transaction valued at 42,595 led to the insider holds 58,969 shares of the business.
Schorno Dean L sold 1,734 shares of RIGL for $38,020 on Feb 05 ’25. The EVP & Chief Financial Officer now owns 57,235 shares after completing the transaction at $21.93 per share. On Feb 04 ’25, another insider, Santos David A, who serves as the EVP, Chief Commercial Officer of the company, sold 2,125 shares for $20.92 each. As a result, the insider received 44,457 and left with 53,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RIGL now has a Market Capitalization of 740211776 and an Enterprise Value of 663948800. As of this moment, Rigel’s Price-to-Earnings (P/E) ratio for their current fiscal year is 6.61, and their Forward P/E ratio for the next fiscal year is 10.03. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.14. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.62 while its Price-to-Book (P/B) ratio in mrq is 6.29. Its current Enterprise Value per Revenue stands at 2.354 whereas that against EBITDA is 5.47.
Stock Price History:
The Beta on a monthly basis for RIGL is 1.09, which has changed by 1.1969697 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, RIGL has reached a high of $52.24, while it has fallen to a 52-week low of $14.63. The 50-Day Moving Average of the stock is 10.76%, while the 200-Day Moving Average is calculated to be 50.21%.
Shares Statistics:
Over the past 3-months, RIGL traded about 627.99K shares per day on average, while over the past 10 days, RIGL traded about 518610 shares per day. A total of 18.14M shares are outstanding, with a floating share count of 17.68M. Insiders hold about 2.65% of the company’s shares, while institutions hold 83.00% stake in the company. Shares short for RIGL as of 1764288000 were 2757766 with a Short Ratio of 4.39, compared to 1761868800 on 3435660. Therefore, it implies a Short% of Shares Outstanding of 2757766 and a Short% of Float of 15.6.
Earnings Estimates
. The current market rating for Rigel Pharmaceuticals (RIGL) reflects the collective analysis of 5.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.8, with high estimates of $0.85 and low estimates of $0.74.
Analysts are recommending an EPS of between $6.92 and $5.95 for the fiscal current year, implying an average EPS of $6.55. EPS for the following year is $4.24, with 5.0 analysts recommending between $5.19 and $3.09.
Revenue Estimates
5 analysts predict $66.44M in revenue for. The current quarter. It ranges from a high estimate of $71.1M to a low estimate of $60.64M. As of. The current estimate, Rigel Pharmaceuticals’s year-ago sales were $57.6MFor the next quarter, 5 analysts are estimating revenue of $59.29M. There is a high estimate of $60.3M for the next quarter, whereas the lowest estimate is $58.27M.
A total of 5 analysts have provided revenue estimates for RIGL’s current fiscal year. The highest revenue estimate was $295.6M, while the lowest revenue estimate was $285.12M, resulting in an average revenue estimate of $290.94M. In the same quarter a year ago, actual revenue was $179.28MBased on 5 analysts’ estimates, the company’s revenue will be $291.58M in the next fiscal year. The high estimate is $356.2M and the low estimate is $264.08M.
